Castrate-resistant prostate cancer represents a significant clinical challenge.
Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors' critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer.
Written by:
Zaborowska M, Szmit S, Szczylik C. Are you the author?
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Reference: Arch Med Sci. 2012 Jul 4;8(3):528-32.
doi: 10.5114/aoms.2012.29408
PubMed Abstract
PMID: 22852011
UroToday.com Prostate Cancer Section
